JP2019530674A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530674A5 JP2019530674A5 JP2019513935A JP2019513935A JP2019530674A5 JP 2019530674 A5 JP2019530674 A5 JP 2019530674A5 JP 2019513935 A JP2019513935 A JP 2019513935A JP 2019513935 A JP2019513935 A JP 2019513935A JP 2019530674 A5 JP2019530674 A5 JP 2019530674A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mammal
- compound according
- optionally substituted
- gpr120
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000124008 Mammalia Species 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 38
- 150000001875 compounds Chemical class 0.000 claims description 35
- 102100040134 Free fatty acid receptor 4 Human genes 0.000 claims description 19
- 101000890672 Homo sapiens Free fatty acid receptor 4 Proteins 0.000 claims description 19
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 14
- 230000003959 neuroinflammation Effects 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 230000004060 metabolic process Effects 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 5
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 4
- 208000004930 Fatty Liver Diseases 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000000155 isotopic effect Effects 0.000 claims description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 4
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 238000007614 solvation Methods 0.000 claims description 3
- 125000003368 amide group Chemical group 0.000 claims description 2
- 125000005392 carboxamide group Chemical class NC(=O)* 0.000 claims description 2
- 150000003857 carboxamides Chemical class 0.000 claims description 2
- 238000010276 construction Methods 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 125000000565 sulfonamide group Chemical class 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662393616P | 2016-09-12 | 2016-09-12 | |
| US62/393,616 | 2016-09-12 | ||
| PCT/US2017/050956 WO2018049324A1 (en) | 2016-09-12 | 2017-09-11 | Monocyclic compounds useful as gpr120 modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019530674A JP2019530674A (ja) | 2019-10-24 |
| JP2019530674A5 true JP2019530674A5 (enExample) | 2020-11-12 |
| JP7086942B2 JP7086942B2 (ja) | 2022-06-20 |
Family
ID=61562455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019513935A Active JP7086942B2 (ja) | 2016-09-12 | 2017-09-11 | Ｇｐｒ１２０モジュレーターとして有用な単環式化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10800773B2 (enExample) |
| EP (1) | EP3509587B1 (enExample) |
| JP (1) | JP7086942B2 (enExample) |
| KR (1) | KR102537985B1 (enExample) |
| CN (1) | CN110225752B (enExample) |
| CA (1) | CA3041033A1 (enExample) |
| WO (1) | WO2018049324A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110225752B (zh) | 2016-09-12 | 2023-05-05 | 整体健康 | 用作gpr120调节器的单环化合物 |
| US10865201B2 (en) * | 2016-09-12 | 2020-12-15 | Valo Health, Inc. | Bicyclic compounds useful as GPR120 modulators |
| WO2019202612A2 (en) * | 2018-04-20 | 2019-10-24 | Krish Biotech Research Private Limited | Method of treatment of non-alcoholic steatohepatitis, nash |
| US11142525B2 (en) * | 2018-11-15 | 2021-10-12 | Pfizer Inc. | Azalactam compounds as HPK1 inhibitors |
| IL297838A (en) | 2020-05-01 | 2023-01-01 | Pfizer | Azalactam compounds as hpk1 inhibitors |
| US20230219927A1 (en) * | 2020-05-08 | 2023-07-13 | Georgiamune Llc | Akt3 modulators |
| CN114671827B (zh) * | 2020-12-24 | 2024-09-20 | 杭州百新生物医药科技有限公司 | 邻苯甲酰磺酰亚胺类衍生物及其应用 |
| KR102605163B1 (ko) * | 2021-06-01 | 2023-11-23 | 연세대학교 산학협력단 | 뇌암의 예방 또는 치료용 조성물 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2735225A (en) * | 1956-02-21 | Table ix p petri dish tests with x-phthalimido- | ||
| DE2253251A1 (de) | 1972-10-30 | 1974-05-09 | Thomae Gmbh Dr K | Neue phthalimido-sulfonylharnstoffe |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US4165435A (en) * | 1976-06-25 | 1979-08-21 | Ciba-Geigy Corporation | Fire retardant s-triazine derivatives |
| DE3474547D1 (en) | 1983-12-02 | 1988-11-17 | Shell Int Research | Diphenyl ether herbicides |
| FR2659327A1 (fr) * | 1990-03-08 | 1991-09-13 | Centre Nat Rech Scient | Derives du benzisothiazolinone-1-dioxyde, utilisables comme inhibiteurs des elastases. |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| DE69224115T2 (de) | 1991-07-30 | 1998-08-20 | Ciba Geigy Ag | Heteroaryl substituierte Hydroxylaminderivate als Lipoxygenase-Inhibitoren |
| US5350761A (en) | 1991-07-30 | 1994-09-27 | Ciba-Geigy Corporation | Indolyl substituted hydroxylamine derivatives |
| TW219935B (enExample) | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
| PT891332E (pt) * | 1996-03-29 | 2004-07-30 | Pfizer | Derivados de 6-fenilpiridil-2-amina |
| US6716836B2 (en) | 2001-03-22 | 2004-04-06 | Boehringer Ingelheim (Canada) Ltd. | Non-nucleoside reverse transcriptase inhibitors |
| GB0124627D0 (en) | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| EP1688138A4 (en) | 2003-11-26 | 2008-01-16 | Takeda Pharmaceutical | AGENT FOR REGULATING THE FUNCTION OF A RECEIVER |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| US8110681B2 (en) | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| AU2007326395B2 (en) | 2006-12-01 | 2012-10-11 | Msd K.K. | Novel phenyl-isoxazol-3-ol derivative |
| MY150746A (en) | 2006-12-27 | 2014-02-28 | Sanofi Aventis | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase |
| JP5175866B2 (ja) | 2007-02-22 | 2013-04-03 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｇタンパク質共役受容体を調節するための化合物および方法 |
| KR20090113382A (ko) | 2007-02-22 | 2009-10-30 | 아이알엠 엘엘씨 | Ｇ 단백질-커플링된 수용체의 조절제로서의 티아졸 유도체 |
| US8318781B2 (en) | 2007-04-26 | 2012-11-27 | Japan Science And Technology Agency | G-protein-conjugated receptor agonist |
| KR101511396B1 (ko) | 2007-07-20 | 2015-04-13 | 추가이 세이야쿠 가부시키가이샤 | ｐ27 단백질 유도제 |
| JPWO2009147990A1 (ja) | 2008-06-02 | 2011-10-27 | Ｍｓｄ株式会社 | 新規イソオキサゾール誘導体 |
| JP2012506386A (ja) | 2008-10-21 | 2012-03-15 | メタボレックス， インコーポレイテッド | アリールｇｐｒ１２０受容体アゴニストおよびその使用 |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| CA2754688A1 (en) * | 2009-03-11 | 2010-09-16 | Msd K.K. | Novel isoindolin-1-one derivative |
| US8314120B2 (en) | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
| EP2582674B1 (en) | 2010-06-16 | 2014-10-01 | Cymabay Therapeutics, Inc. | Gpr120 receptor agonists and uses thereof |
| US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
| CA2841757A1 (en) | 2011-07-15 | 2013-01-24 | Etzer Darout | Gpr 119 modulators |
| AR088989A1 (es) | 2011-11-30 | 2014-07-23 | Hoffmann La Roche | Derivados biciclicos de dihidroisoquinolin-1-ona |
| WO2013139341A1 (en) | 2012-03-20 | 2013-09-26 | Syddansk Universitet | Gpr120 receptor modulators |
| CA2887348A1 (en) * | 2012-10-11 | 2014-04-17 | Merck Sharp & Dohme Corp. | Substituted spiropiperidinyl compounds useful as gpr120 agonists |
| KR101942752B1 (ko) | 2012-11-05 | 2019-01-28 | 주식회사 엘지화학 | Ｇｐｒ120 효능제로서의 티오아릴 유도체 |
| RU2015123982A (ru) | 2012-12-03 | 2017-01-13 | Ф. Хоффманн-Ля Рош Аг | Соединения замещенных триазола и имидазола |
| US9714252B2 (en) | 2012-12-20 | 2017-07-25 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
| CA2905729C (en) | 2013-03-14 | 2021-11-09 | Janssen Pharmaceutica Nv | Bicyclic pyrrole derivatives useful as agonists of gpr120 |
| CA2905428A1 (en) | 2013-03-14 | 2014-10-02 | Bristol-Myers Squibb Company | Bicyclo [2.2.1] acid gpr120 modulators |
| WO2014159054A1 (en) | 2013-03-14 | 2014-10-02 | Janssen Pharmaceutica Nv | Gpr120 agonists for the treatment of type ii diabetes |
| EP2970157B1 (en) | 2013-03-14 | 2018-04-25 | Janssen Pharmaceutica NV | Benzo-fused heterocyclic derivatives useful as agonists of gpr120 |
| US8962660B2 (en) | 2013-03-14 | 2015-02-24 | Bristol-Myers Squibb Company | Oxabicyclo [2.2.2] acid GPR120 modulators |
| ES2784489T3 (es) | 2013-06-27 | 2020-09-28 | Lg Chemical Ltd | Derivados de biarilo como agonistas de GPR120 |
| AR099937A1 (es) | 2014-04-04 | 2016-08-31 | Sanofi Sa | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
| AR100328A1 (es) * | 2014-05-07 | 2016-09-28 | Bristol Myers Squibb Co | Moduladores pirrolidina de gpr40 |
| JP2017527559A (ja) | 2014-08-29 | 2017-09-21 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | ハンチントンタンパク質のイメージング用プローブ |
| JP6486699B2 (ja) * | 2015-01-29 | 2019-03-20 | 国立大学法人金沢大学 | 脱水縮合剤 |
| ES2989326T3 (es) | 2015-10-21 | 2024-11-26 | Otsuka Pharma Co Ltd | Compuestos de benzolactama como inhibidores de la proteína cinasa |
| CN110225752B (zh) | 2016-09-12 | 2023-05-05 | 整体健康 | 用作gpr120调节器的单环化合物 |
| US10865201B2 (en) | 2016-09-12 | 2020-12-15 | Valo Health, Inc. | Bicyclic compounds useful as GPR120 modulators |
-
2017
- 2017-09-11 CN CN201780068713.3A patent/CN110225752B/zh active Active
- 2017-09-11 JP JP2019513935A patent/JP7086942B2/ja active Active
- 2017-09-11 US US16/331,916 patent/US10800773B2/en active Active
- 2017-09-11 EP EP17849719.4A patent/EP3509587B1/en active Active
- 2017-09-11 CA CA3041033A patent/CA3041033A1/en active Pending
- 2017-09-11 KR KR1020197010269A patent/KR102537985B1/ko active Active
- 2017-09-11 WO PCT/US2017/050956 patent/WO2018049324A1/en not_active Ceased
-
2020
- 2020-08-20 US US16/998,660 patent/US11548886B2/en active Active
-
2022
- 2022-10-03 US US17/959,064 patent/US12116362B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530674A5 (enExample) | ||
| JP2019533642A5 (enExample) | ||
| JP2019519598A5 (enExample) | ||
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| RU2470011C2 (ru) | Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов | |
| JP2020500862A5 (enExample) | ||
| JP2018518537A5 (enExample) | ||
| JP2013010792A5 (enExample) | ||
| JP2006509749A5 (enExample) | ||
| JP2019524865A5 (enExample) | ||
| JP2013010793A5 (enExample) | ||
| JP2020528889A5 (enExample) | ||
| JP2020502047A5 (enExample) | ||
| JP2019506430A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| JP2018021046A5 (enExample) | ||
| JP2017526716A5 (enExample) | ||
| JP2005519916A5 (enExample) | ||
| JP2021105002A5 (enExample) | ||
| JP2007523155A5 (enExample) | ||
| JP2012522759A5 (enExample) | ||
| RU2002100254A (ru) | Анестетическая композиция, включающая антагонист nmda b альфа-2 адренергический агонист | |
| JP2017511339A5 (enExample) | ||
| JP2019535761A5 (enExample) | ||
| JP2019505529A5 (enExample) |